Search Within

Mario E Lacouture

Formats
  1. Journal Article (220)
  2. Meeting Abstract (171)
  3. Book Section (25)
  4. Review (18)
  5. Research Letter (9)
  6. Guidelines (5)
  7. Book Whole (2)
  8. Conference Paper (2)
  9. Editorial (2)
  10. Miscellaneous (2)
  11. Correspondence (1)
Groups
  1. Department of Medicine (457)
  2. Dermatology (457)
  3. Dermatology Service (457)
  4. Division of Subspecialty Medicine (457)
  5. Survivorship Research (457)
  6. Solid Tumor Oncology Division (142)

More Groups

People
  1. Viswanath Reddy Belum (37)
  2. Shari Goldfarb (34)
  3. Alina Markova (31)
  4. Azael Freites Martinez (27)
  5. Yevgeniy Balagula (26)
  6. Stephen Dusza (25)

More People

Years
  1. 2025 (4)
  2. 2024 (17)
  3. 2023 (24)
  4. 2022 (31)
  5. 2021 (32)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Journal of the American Academy of Dermatology (51)
  3. Annals of Oncology (20)
  4. Supportive Care in Cancer (17)
  5. The Oncologist (16)
  6. Blood (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (92)
  2. Mosby Elsevier (55)
  3. Oxford University Press (44)
  4. Elsevier Inc. (35)
  5. Springer (34)
  6. Wiley Blackwell (29)

More Publishers

Results (457)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dermatologic adverse events of systemic anticancer therapies: Cytotoxic chemotherapy, targeted therapy, and immunotherapy
    Review

    Deutsch, A.; Leboeuf, N. R.; Lacouture, M. E.; McLellan, B. N.
    American Society of Clinical Oncology Educational Book (2020)

    Fulltext@MSK | Save
  • Vitiligo following autologous hematopoietic stem cell transplantation
    Journal Article

    Nguyen, J.; Singh, N.; Afifi, S.; Giralt, S.; Lacouture, M. E.; Busam, K. J.; Hassoun, H.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Eosinophilic fasciitis following checkpoint inhibitor therapy: Four cases and a review of literature
    Review

    Chan, K. K.; Magro, C.; Shoushtari, A.; Rudin, C.; Rotemberg, V.; Rossi, A.; Lezcano, C.; Carrino, J.; Fernandez, D.; Postow, M. A.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: A randomised, placebo-controlled phase II trial
    Journal Article

    Vincenzi, B.; Trower, M.; Duggal, A.; Guglielmini, P.; Harris, P.; Jackson, D.; Lacouture, M. E.; Ratti, E.; Tonini, G.; Wood, A.; more...
    BMJ Open (2020)

    Fulltext@MSK | Save
  • Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation
    Meeting Abstract

    Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Anticancer therapies
    Book Section

    Sibaud, V.; Baran, R.; Piraccinic, B. M.; Lacouture, M. E.; Robert, C.
    In Baran, R.; de Berker, D.; Holzberg, M.; Piraccinic, B. M.; Richert, B.; Thomas, L. (Eds.) Baran & Dawber’s Diseases of the Nails and their Management. 5th ed (2019)

    Fulltext@MSK | Save
  • Cutaneous adverse events of systemic melanoma treatments
    Book Section

    Menzer, C.; Chen, S. T.; Phillips, G. S.; Lacouture, M. E.
    In Fisher, D. E.; Bastian, B. C. (Eds.) Melanoma (2019)

    Fulltext@MSK | Save
  • Dermatologic adverse events from cancer treatments
    Book Section

    Wu, J.; Markova, A.; Lacouture, M. E.
    In Shear, N. H.; Dodiuk-Gad, R. P. (Eds.) Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends (2019)

    Fulltext@MSK | Save
  • Dermatologic cancer pain syndromes
    Book Section

    Svigos, K.; Belum, V. R.; Lacouture, M. E.
    In Gulati, A.; Puttanniah, V.; Bruel, B. M.; Rosenberg, W. S.; Hung, J. C. (Eds.) Essentials of Interventional Cancer Pain Management (2019)

    Fulltext@MSK | Save
  • Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events
    Journal Article

    Hawerkamp, H. C.; Kislat, A.; Gerber, P. A.; Pollet, M.; Rolfes, K. M.; Soshilov, A. A.; Denison, M. S.; Momin, A. A.; Arold, S. T.; Datsi, A.; more...
    Allergy: European Journal of Allergy and Clinical Immunology (2019)

    Fulltext@MSK | Save